CoChat

Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders

Zhou, Melissa S., Nasir, Madeeha, Farhat, Luis C., Kook, Minjee, Artukoglu, Bekir B., Bloch, Michael H. · 2021 · Journal of the American Academy of Child & Adolescent Psychiatry
Cited by 121

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

OBJECTIVE To examine the efficacy of pharmacological treatments for restricted and repetitive behaviors (RRBs) in autism spectrum disorder (ASD). METHOD We searched PubMed, Embase, and CENTRAL to identify all double-blind, randomized, placebo-controlled trials that examined the efficacy of pharmacological agents in the treatment of autism spectrum disorders and measured restricted and repetitive behaviors as an outcome. Our primary outcome was standardized mean difference in rating scales of RRBs. RESULTS We identified 64 randomized, placebo-controlled trials involving 3,499 participants with ASD. Antipsychotics significantly improved RRB outcomes compared to placebo [standardized mean difference (SMD)=0.28 (95% Confidence Interval (CI): 0.08-0.49), z=2.77, p=0.01] demonstrating a small effect size. Larger significant positive effects on RRBs in ASD were seen in individual studies with fluvoxamine, buspirone, bumetanide, divalproex, guanfacine, and folinic acid that have not been replicated. Other frequently studied pharmacological treatments in ASD including oxytocin, omega-3 fatty acids, selective serotonin reuptake inhibitors (SSRI) and methylphenidate did not demonstrate significant benefit in reducing RRB compared to placebo [oxytocin: SMD=0.23 (95% CI: -0.01-0.47), z=1.85, p= 0.06; omega-3 fatty acids: SMD = 0.19 (95% CI: -0.05-0.43), z= 1.54, p = 0.12; SSRI: SMD=0.09 (95% CI: -0.21-0.39), z=0.60, p=0.56; methylphenidate: SMD=0.18 (95% CI: -0.11-0.46), z=1.23, p=0.22]. CONCLUSION The results of the present meta-analysis suggest that currently available pharmacological agents have at best only a modest benefit for the treatment of RRBs in ASD with the most evidence supporting antipsychotic medications. Additional RCTs with standardized study designs and consistent and specific assessment tools for RRBs, are needed to further understand how we can best help ameliorate these behaviors in individuals with ASD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaac.2020.03.007

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

Metadata

Authors
Zhou, M. S., Nasir, M., Farhat, L. C., Kook, M., Artukoglu, B. B., & Bloch, M. H.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2021-01
Volume
60
Issue
1
Pages
35-45
ISSN
0890-8567 (ISSN-L)
OpenAlex
W3022320953
Cited by
121
References
31
FWCI
8.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.